From PCOS to PMOS - What the Name Change Means for You
If you have been diagnosed with polycystic ovary syndrome - or suspect you might have it - you may have seen recent headlines about a name change. As of 2026, the condition is being officially renamed to polyendocrine metabolic ovarian syndrome, or PMOS for short.
It is not just a rebrand. The new name reflects a much better understanding of what this condition actually is - and that matters for how it gets diagnosed, treated and taken seriously. Over 22,000 people - including clinicians, researchers and patients - were surveyed over several years to contribute to this name change, and let’s talk about why it’s a real win for women’s health.
Why the old name was problematic
“Polycystic Ovary Syndrome” or PCOS was never an appropriate name, and contributed to years of challenges with women being misdiagnosed or not taken seriously.
Firstly, the "cysts" that the name refers to are not actually cysts. They are small, immature follicles - a normal part of ovarian biology that, in this condition, do not develop and release an egg the way they typically would. Some people with the condition do not even have these follicles visible on ultrasound at all.
More importantly, ovarian changes are only one piece of a much bigger puzzle. The condition can have far broader impacts involving multiple hormonal systems, metabolism, skin and mental health.
The old name made it easy to dismiss as a reproductive issue. Many people have experienced exactly that - being told it only matters if they are trying to conceive, or having their metabolic symptoms overlooked entirely.
This has had negative impacts on the understanding, awareness, clinical management and support available to women who have been impacted by this condition.
What PMOS actually stands for
The renaming was a major global effort. Researchers at Monash University in Australia led the process, alongside international clinical and patient advocacy groups. The goals were to reduce stigma, improve accuracy and make sure the name reflected the hormonal and metabolic nature of the condition.
The new name was chosen to better capture what is really going on.
Polyendocrine - meaning multiple hormone systems are involved, not just the ovaries.
Metabolic - acknowledging the strong links to insulin resistance and cardiometabolic health.
Ovarian - the reproductive dimension is still there.
Syndrome - reflecting a collection of features that can look quite different from person to person, not one single cause.
Does this change how the condition is managed?
Nothing will change overnight, but the overall purpose of this change is to improve the diagnosis, outcomes and care for the 170 million women worldwide (1 in 8) who are impacted by this condition.
When a condition is named after a single organ, it tends to get managed in a single specialty. For years, this condition has sat largely within the fertility space. The new name reflects the need for a much broader approach to care, involving multiple health disciplines.
The name change reflects years of scientific progress in understanding this condition, and marks a key step toward increasing global awareness. This has implications for research funding, clinical understanding and the way the condition is managed.
It also validates what many people with the condition have been saying for years: this is not "just" a period problem. It can affect energy, skin, hair, weight, mood, fertility and long-term health - and it deserves to be recognised accordingly.
What to expect during the transition
Both names - PCOS and PMOS - will likely be used side by side for a while. A three-year implementation plan is underway to update clinical guidelines, medical education and disease classification systems internationally. You may see your GP or specialist still using the old term as the transition rolls out.
Ultimately, the name is catching up with the science. And when we name a condition more accurately, we create space for better conversations, better care and better outcomes.
Reference:
Teede, H. J., Khomami, M. B., Morman, R., Laven, J. S. E., Joham, A. E., Costello, M. F., Patil, M., Rees, D. A., Berry, L., Cree, M. G., Zhao, H., Norman, R. J., Dokras, A., Piltonen, T., & Global Name Change Consortium (2026). Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet (London, England), S0140-6736(26)00717-8. Advance online publication. https://doi.org/10.1016/S0140-6736(26)00717-8
Disclaimer: This article is for informational purposes only and does not constitute medical advice. If you have or suspect you may have PMOS, work with a qualified healthcare professional to guide your management.